Article Details

Alzheimer's drugmakers seek accelerated FDA review despite decision to limit coverage

Retrieved on: 2022-04-13 18:19:56

Tags for this article:

Click the tags to see associated articles and topics

Alzheimer's drugmakers seek accelerated FDA review despite decision to limit coverage. View article details on HISWAI: https://www.econotimes.com/Alzheimers-drugmakers-seek-accelerated-FDA-review-despite-US-coverage-decision-1631243

Excerpt

... Eisai's lecanemab and Lilly's donanemab are monoclonal antibodies that ... a fourth plaque-targeting antibody, although it is not pursuing an ...

Article found on: www.econotimes.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up